Fig. 3: Treatment response and remission in the MDMA-AT (n = 53) and placebo with therapy (n = 50) groups.
From: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
A ≥10-point reduction in CAPS-5 total severity score was considered to be clinically meaningful. Responders (≥10-point reduction from baseline), loss of diagnosis (≥10-point reduction from baseline and no longer meeting PTSD diagnostic criteria) and remission (loss of diagnosis and CAPS-5 total severity score of 11 or less) were tracked in both groups as a percentage of participants. Non-responders were defined as any CAPS-5 total severity score change <10-point reduction from baseline.
